| Similarity | Rank | |
|---|---|---|
| placebo-controlled | 0.933 | 42426 |
| double-blind | 0.926 | 34234 |
| multicenter | 0.904 | 69465 |
| randomized | 0.898 | 18214 |
| randomised | 0.860 | 46929 |
| once-daily | 0.829 | 95649 |
| monotherapy | 0.827 | 66795 |
| case-control | 0.792 | 83586 |
| bevacizumab | 0.785 | 94024 |
| Randomized | 0.779 | 93743 |
| high-dose | 0.778 | 58378 |
| placebo | 0.777 | 12334 |
| investigational | 0.777 | 62099 |
| meta-analysis | 0.772 | 39189 |
| tolerability | 0.765 | 68898 |
| preclinical | 0.763 | 49806 |
| RCTs | 0.762 | 82390 |
| ribavirin | 0.759 | 98039 |
| dose-response | 0.758 | 97933 |
| antiplatelet | 0.756 | 82232 |
| prospectively | 0.753 | 71458 |
| pharmacokinetic | 0.751 | 73658 |
| low-dose | 0.749 | 57276 |
| adjunctive | 0.747 | 74163 |
| pharmacologic | 0.746 | 72757 |